Statement of Changes in Beneficial Ownership (4)
September 17 2020 - 05:26PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
1. Name
and Address of Reporting Person * Schoen
Eric |
2. Issuer Name and Ticker or Trading
Symbol CASSAVA SCIENCES INC [ SAVA ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)_____
Director _____
10% Owner
__X__ Officer (give title
below) _____ Other
(specify below)
Chief Financial Officer |
(Last)
(First)
(Middle)
C/O CASSAVA SCIENCES, INC., 7801 N. CAPITAL OF TEXAS HWY.;
SUITE 260 |
3. Date of Earliest Transaction (MM/DD/YYYY)
9/17/2020
|
(Street)
AUSTIN, TX 78731
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or
Beneficially Owned
|
1.Title of Security
(Instr. 3) |
2. Trans. Date |
2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following
Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) |
7. Nature of Indirect Beneficial Ownership (Instr.
4) |
Code |
V |
Amount |
(A) or (D) |
Price |
Common Stock |
9/17/2020 |
|
P |
|
10000 |
A |
$7.03 (1) |
25300 |
D |
|
Common Stock |
9/17/2020 |
|
P |
|
2000 |
A |
$7.04 |
27300 |
I |
Purchase by Schoen Family LLC. Reporting person
is a member of the Schoen Family LLC. |
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative
Security |
3. Trans. Date |
3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying
Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially
Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct
(D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr.
4) |
Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Explanation of
Responses: |
(1) |
The purchase reported in
column 4 is a weighted average price. The shares were purchased in
multiple transactions at prices ranging from $7.01 to $7.04 per
share. The reporting person undertakes to provide to Cassava, any
security holder of Cassava or the staff of the Securities and
Exchange Commission, upon request, full information regarding the
number of shares acquired at each price within the range set forth
in this footnote. |
Reporting
Owners
|
Reporting Owner Name / Address |
Relationships
|
Director |
10% Owner |
Officer |
Other |
Schoen Eric
C/O CASSAVA SCIENCES, INC.
7801 N. CAPITAL OF TEXAS HWY.; SUITE 260
AUSTIN, TX 78731 |
|
|
Chief Financial Officer |
|
Signatures
|
/s/Eric J. Schoen |
|
9/17/2020 |
**Signature of
Reporting Person |
Date |